A broad, regional system to lower the temperature of resuscitated cardiac arrest patients at a centrally-located hospital improved outcomes, according to a study in Circulation: Journal of the American Heart Association.
Cooling treatment, or therapeutic hypothermia, is effective yet underused, researchers said.
A network of first responders, EMS departments and more than 30 independent hospitals within 200 miles of Minneapolis, Minn., and Abbott Northwestern Hospital collaborated to implement the protocol.
"We've shown that a fully integrated system of care, from EMS through hospital discharge, can provide this essential therapy to victims of out-of-hospital cardiac arrest across a broad geographic region," said Michael Mooney, M.D., the study's lead author and director of the therapeutic hypothermia program at Minneapolis Heart Institute, where the protocol was developed.
Researchers tracked 140 patients who suffered out-of-hospital cardiac arrest between February 2006 and August 2009. Although their heartbeat and circulation were restored within an hour of collapse, they remained unresponsive.
Ice packs were used to begin the cooling process, which started during initial EMS transport to the hospital and in the emergency departments of the network hospitals. One hundred forty patients were admitted to Abbott Northwestern Hospitals for therapeutic hypothermia and re-warming — 107 of those were transferred from other hospitals.
Over three to four hours, the patients' core body temperature was lowered to about 92 degrees Fahrenheit and maintained at that temperature for about 24 hours.
Over the next eight hours, physicians gradually re-warmed them to a normal temperature.
Researchers found that:
"What our data show is if you have a cardiac arrest 200 miles away or on our doorstep, the quality of the outcomes is identical," Mooney said.
About 300,000 out-of-hospital cardiac arrests occur in the United States each year and most are fatal, according to the American Heart Association.
If a cardiac arrest patient survives the initial loss of oxygen from their arrest, they then face the destruction that unfolds after their blood flow is rapidly restored, which is devastating and often fatal.
Therapeutic hypothermia blunts the damage that can occur in the 16-hour window after bloodflow is restored. The American Heart Association and other experts recommend therapeutic hypothermia, but U.S. cardiologists have been slow to use it.
The efficiencies of the area's existing network, transfer agreements and working relationships between the EMS departments, network hospitals and the central hospital helped Mooney and his colleagues implement the protocol.
About half of all patients received therapeutic hypothermia while also being treated for a severe form of heart attack (ST-elevation myocardial infarction) in the catheterization lab, said Barbara Unger, R.N., co-author of the study and director of cardiovascular emergency program development for the Minneapolis Heart Institute.
The average age of patients in the study was 62 and 77 percent were men. Older patients fared slightly worse neurologically, the study found.
Co-authors are: Lori L. Boland, M.P.H.; M. Nicholas Burke, M.D.; Kalie Y. Kebed, B.S.; Kevin J. Graham, M.D.; Timothy D. Henry, M.D.; William T. Katsiyiannis, M.D.; Paul A. Satterlee, M.D.; Sue Sendelbach, Ph.D., R.N., C.C.N.S.; James S. Hodges, Ph.D.; and William M. Parham, M.D. Author disclosures are on the manuscript.
The Minneapolis Heart Institute Foundation funded the study.
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.americanheart.org/corporatefunding.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.